Health knowledge made personal
Join this community!
› Share page:
Go
Search posts:

Use of Suppressive Oligonucleotides to Treat Uveitis

Posted Sep 30 2008 5:00pm

Description of Invention:
Uveitis is a major cause of visual loss in industrialized nations. Uveitis refers to an intraocular inflammation of the uveal tract, namely, the iris, choroids, and ciliary body. Uveitis is responsible for about ten percent (10 %) of the legal blindness in the United States. Complications associated with uveitis include posterior synechia, cataracts, glaucoma and retinal edema.

Suppressive CpG oligodeoxynucleotides (ODNs) are ODNs capable of reducing an immune response, such as inflammation. Suppressive ODNs are DNA molecules of at least eight nucleotides in length, where the ODN forms a G-tetrad, and has a circular dichroism value greater than 2.9. In a suppressive ODN, the number of guanosines is at least two.

This application claims compositions and methods for the treatment of uveitis. Specifically, the application claims use of suppressive CpG ODNs to treat uveitis. The compositions and methods of the application can be used for the treatment of anterior, posterior and diffuse uveitis.

Applications:
Vaccine adjuvants, production of vaccines, immunotherapeutics.

Development Status:
Preclinical studies have been performed; oligonucleotides have been synthesized.

Inventors:
Dennis M Klinman (FDA)
Chaiki Fujimoto (NEI)
Igal Gery (NEI)


Patent Status:
HHS, Reference No. E-152-2004/0
PCT, Application No. PCT/US2005/15761 filed 05 May 2005
US, Application No. 11/579,518 filed 03 Nov 2006

International filings in Australia, Canada, China, Europe, India, Japan, Mexico

Licensing Status:
Available for exclusive or nonexclusive licensing.

Collaborative Research Opportunity:
The National Cancer Institute, Laboratory of Experimental Immunology, Immune Modulation Group, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. Please contact John D. Hewes, Ph.D. at 301-435-3121 or hewesj@mail.nih.gov for more information.


Portfolios:
Infectious Diseases
Infectious Diseases - Therapeutics
Infectious Diseases - Vaccines
Rare Diseases



For Additional Information Please Contact:
Peter Soukas J.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325 Room 14,
Rockville, MD 20852-3804
United States
Email: soukasp@mail.nih.gov
Phone: 301-435-4646
Fax: 301-402-0220


Ref No: 1739

Updated: 10/2008

Post a comment
Write a comment:

Related Searches